A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression ...
Pfizer’s Braftovi regimen nearly doubles median progression-free survival in metastatic colorectal cancer: New York Tuesday, June 2, 2026, 10:00 Hrs [IST] Pfizer Inc. announced ...
(NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar ...
Obesity does not just enlarge fat stores, it appears to rework the body’s wiring and immune landscape in ways scientists have ...
BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced full enrollment ...
EMA committee recommends approval of Pierre Fabre Labs Braftovi in combo with cetuximab and Folfox to treat adult patients with BRAFV600E- mCRC: Castres, France Tuesday, May 26, 2 ...
Gulf Business on MSN
DMCC launches incentives package to cut costs for 26,000 Dubai businesses
New companies can benefit from a 10 per cent discount on one-year licence packages and a 20 per cent discount on multi-year business set-up packages, subject to certain programme exclusions ...
Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites June 2, 2026 4:15 PM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results